The Congressional Budget Office estimates that about 750,000 employees could be furloughed each day during the shutdown at a daily cost of roughly $400 million, though that cost would fall if the ...

President Trump described his administration’s agreement with Pfizer on several drug pricing plans as a historic measure to lower costs for Americans. But policy experts said it’s not clear how much ...

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Chelsea Cirruzzo is a Washington correspondent at STAT, where she ...

Matthew Herper covers medical innovation — both its promise and its perils. Amid all the hand-shaking and back-patting, it was perhaps the word “friendship” that stood out the most when the CEO of ...

Hundreds of hospital at home programs are shutting down as Medicare’s pandemic-era waiver nears expiration, straining ERs and patient care nationwide.

Pfizer will offer discounted prices on some of its drugs and avoid U.S. tariffs, in a deal with President Trump.

Ne’eman is an assistant professor of health policy and management at the Harvard T.H. Chan School of Public Health. When it comes to developmental disability, the Kennedy legacy is as storied as ...

Pioneering embryologist Shoukhrat Mitalipov reported that his team has encountered hurdles in creating functional human eggs in the lab ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

Indivior is halting Opvee promotion after a New York settlement. Critics say the overdose drug is overpriced, risky, and no safer than widely used naloxone.

Good morning. The FDA’s top drug regulator posted a highly unusual critique of a drug on his personal LinkedIn account yesterday that immediately got biotech investors talking and speculating. We’ll ...

Is the FDA's top drug regulator, trying to exact revenge on a prominent Wall Street investor after a run-in with him six years ago?